Brief: Theriva Biologics Announces Presentation Of Data From Cohort 1 Of The Phase 1B/2A Clinical Trial Of Syn-004 (Ribaxamase) In Allogeneic Hematopoietic Cell Transplant Recipients
13/04/2023 13:57
April 13 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS ANNOUNCES PRESENTATION OF DATA FROM
COHORT 1
OF THE PHASE 1B/2A CLINICAL TRIAL OF SYN-004 (RIBAXAMASE) IN
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS
Source text for Eikon: ID:nGNXbF0pGF
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025